MET AMPLIFICATION Detail (hg19) (MET)
Information
Genome
| Assembly | Position |
|---|---|
| hg19 | chr7:116,312,459-116,436,396 |
| hg38 | chr7:116,672,405-116,796,342 View the variant detail on this assembly version. |
Summary
MGeND
| Clinical significance | |
| Variant entry | |
| GWAS entry | |
| Disease area statistics | Show details |
ClinVar
| Clinical Significance | |
| Review star | [No Data.] |
| Show details | |
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
| Disease | Drug | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| lung adenocarcinoma | Gefitinib,Erlotinib | C |
Predictive
|
Supports
|
Resistance |
N/A
|
2 | 23470965 | Detail |
| glioblastoma | Crizotinib | C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 22162573 | Detail |
| lung non-small cell carcinoma | Crizotinib | D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 21716144 | Detail |
| colorectal cancer | Crizotinib,Vemurafenib | C |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
4 | 27325282 | Detail |
| lung adenocarcinoma | Crizotinib | C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 25922291 | Detail |
| lung non-small cell carcinoma | Crizotinib | C |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
2 | 27664533 | Detail |
| cancer | Crizotinib | C |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
3 | 25232318 | Detail |
| colorectal cancer | Anti-EGFR Monoclonal Antibody | D |
Predictive
|
Supports
|
Resistance | Somatic | 3 | 23729478 | Detail |
| colorectal cancer | Cetuximab,Crizotinib | D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 23729478 | Detail |
| gastric adenocarcinoma | Onartuzumab | C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 22389872 | Detail |
| lung non-small cell carcinoma | Gefitinib | D |
Predictive
|
Supports
|
Resistance | Somatic | 4 | 17463250 | Detail |
| lung non-small cell carcinoma | Crizotinib | C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 21623265 | Detail |
| lung adenocarcinoma | Crizotinib | C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 26724472 | Detail |
| lung squamous cell carcinoma | Crizotinib | C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 24192513 | Detail |
DisGeNET
[No Data.]
Annotation
Annotations
| Descrption | Source | Links |
|---|---|---|
| 155 patients with lung adenocarcinomas underwent rebiopsy and genotyping (EGFR, AKT1, BRAF, ERBB2, K... | CIViC Evidence | Detail |
| A 62 year old female was diagnosed with glioblastoma (GBM) WHO grade 4. Treatment included radiation... | CIViC Evidence | Detail |
| 2 MET amplified NSCLC cell lines (EBC-1 and H1993), as well as 2 EGFR mutant and 2 MET and EGFR wild... | CIViC Evidence | Detail |
| Case report of a patient with BRAF V600E mutant metastatic colorectal cancer. Combined EGFR and BRAF... | CIViC Evidence | Detail |
| In an evaluation of a patient with crizotinib-sensitive lung adenocarcinoma, an MET-Amplification wa... | CIViC Evidence | Detail |
| Case report of two patients with MET amplification (MET:CEP7 ratio ≥5) and no concomitant MET exon 1... | CIViC Evidence | Detail |
| Case report of a 59-year-old white female patient (60 pack-years) with a CUP-syndrome. Molecular pro... | CIViC Evidence | Detail |
| Functional studies show that MET activation confers resistance to anti-EGFR therapy both in vitro an... | CIViC Evidence | Detail |
| Functional studies show that MET activation confers resistance to anti-EGFR therapy both in vitro an... | CIViC Evidence | Detail |
| A case-study describing a patient with MET polysomy, MET over-expression and evidence of autocrine H... | CIViC Evidence | Detail |
| In this study a gefitinib-sensitive cell-line (HCC827), acquired gefitinib resistance (HCC827 GR) by... | CIViC Evidence | Detail |
| A case-study of an ALK-negative patient with MET amplification (MET/CEP7 ratio >5.0) who achieved a ... | CIViC Evidence | Detail |
| Case report of a patient with MET amplification without high-level MET/CEP7 ratio, MET exon 14 mutat... | CIViC Evidence | Detail |
| Case report of a 73 year old patient with advanced squamous cell carcinoma of the lung that tested n... | CIViC Evidence | Detail |
Overlapped Transcript Coordinates
| Gene | Transcript ID | Exon Number | Chromosome | Start | Stop | Type | Amino Mutation | Transcript Position | Links |
|---|
Overlapped Transcript
| Gene | Transcript ID | Chromosome | Start | Stop | Links |
|---|
- Gene
- MET
- Genome
- hg19
- Position
- chr7:116,312,459-116,436,396
- Variant Type
- cnv
- Variant (CIViC) (CIViC Variant)
- AMPLIFICATION
- Transcript 1 (CIViC Variant)
- ENST00000318493.6
- Variant URL (CIViC Variant)
- https://civic.genome.wustl.edu/links/variants/270
Genome browser